You can use your existing Medical Independent, MediLearning or PharmacistCPD account to log in. is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.

The benefits of registering: only registered users:
  • receive the ecCopy two days prior to the printed edition.
  • have automatic access to our free CPD sites.
  • can partake in our online MCQs.
  • can enter our online sports quiz.

Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

Download the new Mindo app for both IOS & Android.

  • Get notified when a story goes live
  • Access Premium Content
  • Read Offline
[the_ad_placement id="main-ldb-public"]
[the_ad_placement id="main-ldb-mobile-public"]

You are reading 1 of 2 free-access articles allowed for 30 days

Inquiry on valproate ‘not required at present’ – Minister

By Dermot - 13th Jul 2018 | 3 views

Minister Harris

In May, the Oireachtas Health Committee recommended the establishment of an independent investigation to examine the historical use of valproate medicines in Ireland and their ongoing effects. The Committee also said the issue of compensation should be examined.

Babies born to women who take valproate-containing medicines during pregnancy have a 30-40 per cent risk of developmental disability and a 10 per cent risk of birth defects. In Ireland, Epilim is licensed for epilepsy and bipolar disorder.

Approximately 400 children may have been affected by FACS, it is understood.

FACS Forum Chair Ms Joan O’Donnell told the <em><strong>Medical Independent (MI)</strong></em>: “Parents need to know how so many cases of foetal valproate syndrome were allowed to happen. The Irish public also deserve answers so that these tragedies do not happen again.

“Some of the complexities that arise in relation to the issue of compensation would also be addressed via an investigation. It is our belief that compensation is not only necessary; it is long overdue.”

Ms O’Donnell said there appeared to be some confusion on the Minister’s part with regard to the issue of an inquiry concerning those already affected, and current actions by the HSE and Health Products Regulatory Authority (HPRA).

“The HSE and HPRA response is based around ensuring that the incidence of FACS is reduced into the future and that appropriate services are provided for those already affected. They do not address the historical issue of potential accountability and the positive developments in recent months do not relieve the State of its responsibility to understand and address these historical issues.”

It is understood the Minister informed the FACS Forum that no decision had been taken on the compensation issue.

Meanwhile, at press time, the HSE had still not written to known recipients of the medicine under community drug schemes, despite urgent internal warnings last October that this must occur. In late May, the HSE said a letter would issue in the coming weeks. Patients should not stop taking the medication without consulting their doctor.

Mr Peter Murphy, CEO of Epilepsy Ireland, commented: “There has now been a delay of over a month in getting the letter out to over 3,000 female valproate patients to advise them on the risks and the steps they should now take in conjunction with their medical team.

“This delay is putting women on valproate and their children at further and unnecessary risk. Many of the women on the HSE’s mailing list will not have any awareness currently of the risks involved and for every week that this project is delayed, there is an increased risk of one or more of these patients becoming pregnant with potentially devastating consequences.”

A draft HSE Valproate Response plan outlining the approach on services and supports is the subject of “ongoing engagement” between the Department of Health and the HSE, according to the Department.

The HSE had not responded by time of publication.

Meanwhile, incidences of Epilim being dispensed in plastic bags without warning materials are still occurring. OACS (Organisation for Anticonvulsant Syndromes) Ireland tweeted an example on 12 July.

Leave a Reply

[the_ad_placement id="main-ldb-public-2"]
[the_ad_placement id="main-ldb-mobile-public-2"]
Latest Issue
The Medical Independent – 24 June 2021

You need to be logged in to access this content. Please login or sign up using the links below.

[the_ad_placement id="main-mpu-public"]
Most Read
[the_ad_placement id="main-ldb-public-2"]
[the_ad_placement id="main-ldb-mobile-public-2"]